Publication:
Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?

Simple item page
dc.contributor.authorsUnal, G.; Dokumaci, A. H.; Hazar-Yavuz, A. N.; Aycan, M. B.; Sahin, C.; Keles, R.; Aricioglu, F.
dc.date.accessioned2022-03-12T16:16:34Z
dc.date.accessioned2026-01-11T09:22:23Z
dc.date.available2022-03-12T16:16:34Z
dc.date.issued2016
dc.identifier.doi10.1016/S0924-977X(16)31560-7
dc.identifier.eissn1873-7862
dc.identifier.issn0924-977X
dc.identifier.urihttps://hdl.handle.net/11424/225781
dc.identifier.wosWOS:000398568302141
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofEUROPEAN NEUROPSYCHOPHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleFamotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPageS527
oaire.citation.startPageS526
oaire.citation.titleEUROPEAN NEUROPSYCHOPHARMACOLOGY
oaire.citation.volume26

Files

Collections

Araştırma Çıktıları